Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14224961 | 1.00 | PDE4D (0.61) | PDE4DEPHX2PRKCAMEN1KMT2A | |
| SCHEMBL29259205 | 0.89 | MEN1 (0.50) | PDE4DMEN1KMT2ATP53 | |
| SCHEMBL6920777 | 0.88 | EPHX2 (0.53) | PDE4DEPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL500451 | 0.83 | MEN1 (0.46) | PDE4DPRKCAMEN1KMT2ATP53 | |
| SCHEMBL30368256 | 0.83 | GALR3 (0.47) | PDE4DMEN1KMT2A | |
| SCHEMBL500452 | 0.83 | MEN1 (0.46) | PDE4DPRKCAMEN1KMT2ATP53 | |
| SCHEMBL29094957 | 0.83 | MEN1 (0.45) | PDE4DMEN1KMT2ATP53 | |
| SCHEMBL11514911 | 0.83 | PDE4D (0.48) | PDE4DEPHX2PRKCA | |
| SCHEMBL11514906 | 0.83 | PDE4D (0.48) | PDE4DEPHX2PRKCA | |
| SCHEMBL29536611 | 0.82 | PPARG (0.58) | EPHX2MEN1KMT2AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946468-B2 | Process for producing ester compound having an internal unsaturated bond or cyclic olefin | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946468-B2 | Process for producing ester compound having an internal unsaturated bond or cyclic olefin | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20120316360-A1 | PROCESS FOR PRODUCING ESTER COMPOUND HAVING a,ß-UNSATURATED BOND | OSAKA UNIVERSITY (JP) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316360-A1 | PROCESS FOR PRODUCING ESTER COMPOUND HAVING a,ß-UNSATURATED BOND | COASY, OXER1, ACSL1 | PDE4D 4370/4885EPHX2 241/4885PRKCA 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.